Nuvectis Pharma completes $100 million public offering

Congratulations to Nuvectis Pharma (NASDAQ: NVCT) on completing a $100 million public offering of common stock.

The company priced 5,000,000 shares at $20.00 per share. Cantor acted as sole bookrunner, with H.C. Wainwright, Laidlaw, Lucid Capital Markets, Maxim Group, Roth Capital Partners and Titan Partners as co-managers.

Proceeds are expected to support continued development of NXP100, NXP200, NXP900 and future product candidates — a meaningful raise at an important moment in the company’s evolution, following its strategic portfolio expansion with Haisco.

Read the full release